News details

Idorsia Japan announces positive results with daridorexant in a Phase 3 study of Japanese patients with insomnia

Idorsia secures additional cash by entering into a building sale and leaseback agreement

Idorsia announces financial results for the first half 2022 – reaching commercial stage

Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension

Phase 2a study results in binge eating disorder

Europe’s first dual orexin receptor antagonist – QUVIVIQ (daridorexant) – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder

Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia

Idorsia announces financial results for the first quarter 2022 – first product launched, second in the starting blocks

PIVLAZ (clazosentan) – Idorsia’s first commercial product – now available for patients in Japan

Idorsia holds its Annual General Meeting of Shareholders

The Journal of Neurosurgery reports impact of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage

New data for daridorexant in patients with insomnia disorder – including long-term safety and efficacy – to be presented at World Sleep 2022

Idorsia issues Notice of the 2022 Annual General Meeting of Shareholders

QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder

Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profitability expected in 2025

Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada

Idorsia appoints Guy Braunstein to Chief Medical Officer and Alberto Gimona to Head of Global Clinical Development

Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg

The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia

Jennifer Aniston partners with Idorsia U.S. to launch ‘Seize the Night & Day’ campaign inspiring Americans to understand their relationship with sleep